Saito Toshiaki, Takahashi Fumiaki, Katabuchi Hidetaka
Gynecology Service, National Kyushu Cancer Center, Fukuoka, Japan.
Clinical Research, Innovation and Education Center, Tohoku University Hospital, Miyagi, Japan.
J Obstet Gynaecol Res. 2017 Nov;43(11):1667-1677. doi: 10.1111/jog.13450. Epub 2017 Sep 11.
The Japan Society of Obstetrics and Gynecology collects and analyzes annual data on gynecologic cancers from member institutions. We present the Patient Annual Report for 2014 and the Treatment Annual Report for 2009. Data on 7436 patients with cervical cancer, 9673 with endometrial cancer, 5924 with ovarian cancer, and 1909 with ovarian borderline tumor for whom treatment was initiated in 2014 were summarized in the Patient Annual Report. Stage I accounted for 55.6%, stage II for 22.9%, stage III for 10.2%, and stage IV for 11.2% of all patients with cervical cancer. Stage I accounted for 72.3%, stage II for 6.0%, stage III for 14.1%, and stage IV for 7.7% of all patients with endometrial cancer. Stage I accounted for 43.3%, stage II for 9.1%, stage III for 27.6%, and stage IV for 7.2% of all patients with ovarian cancer. Data on the prognosis of 4126 patients with cervical cancer, 4613 with endometrial cancer, and 3205 with ovarian cancer for whom treatment was initiated in 2009 were analyzed in the Treatment Annual Report. Survival was analyzed by using the Kaplan-Meier method, the log-rank test and the Wilcoxon test. The 5-year overall survival rates for patients with cervical cancer were 92.4% for stage I, 76.7% for stage II, 54.3% for stage III, and 25.2% for stage IV. The equivalent rates for patients with endometrial cancer were 94.6%, 89.4%, 78.3%, and 25.0%, respectively; and those for patients with ovarian cancer (surface epithelial-stromal tumors) were 90.5%, 78.8%, 46.0%, and 25.1%, respectively.
日本妇产科学会收集并分析了会员机构提供的妇科癌症年度数据。我们展示了2014年患者年度报告和2009年治疗年度报告。2014年开始接受治疗的7436例宫颈癌患者、9673例子宫内膜癌患者、5924例卵巢癌患者以及1909例卵巢交界性肿瘤患者的数据汇总在患者年度报告中。在所有宫颈癌患者中，I期占55.6%，II期占22.9%，III期占10.2%，IV期占11.2%。在所有子宫内膜癌患者中，I期占72.3%，II期占6.0%，III期占14.1%，IV期占7.7%。在所有卵巢癌患者中，I期占43.3%，II期占9.1%，III期占27.6%，IV期占7.2%。2009年开始接受治疗的4126例宫颈癌患者、4613例子宫内膜癌患者和3205例卵巢癌患者的预后数据在治疗年度报告中进行了分析。采用Kaplan-Meier法、对数秩检验和Wilcoxon检验对生存率进行分析。宫颈癌患者的5年总生存率I期为92.4%，II期为76.7%，III期为54.3%，IV期为25.2%。子宫内膜癌患者的相应生存率分别为94.6%、89.4%、78.3%和25.0%；卵巢癌（表面上皮-间质肿瘤）患者的相应生存率分别为90.5%、78.8%、46.0%和25.1%。
